Mechanisms of resistance in bacteria: An evolutionary approach

Open Microbiology Journal

Volumn 7, Issue SPEC.ISSUE.1, 2013, Pages 53-58

  Martins, Ana ^a,b   Hunyadi, Attila ^b,c   Amaral, Leonard ^a,c  

^a INSTITUTO DE HIGIENE E MEDICINA TROPICAL   (Portugal)

^b UNIVERSITY OF SZEGED   (Hungary)

^c EUROPEAN COMMISSION   (Belgium)

Author keywords

Acquisition of resistance; Efflux pumps; Multi drug resistance

Indexed keywords

ANTIBIOTIC AGENT; ISONIAZID; LIPOPOLYSACCHARIDE; PORIN; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; BACTERIAL MUTATION; BACTERIAL STRAIN; BACTERIUM EFFLUX PUMP; EVOLUTIONARY ADAPTATION; GENE OVEREXPRESSION; MICROBIAL MORPHOLOGY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MUTATIONAL ANALYSIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; QUORUM SENSING; REVIEW; SIGNAL TRANSDUCTION;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; MYCOBACTERIUM TUBERCULOSIS; SALMONELLA SP.; STAPHYLOCOCCUS AUREUS;

EID: 84876079475     PISSN: None     EISSN: 18742858     Source Type: Journal    
DOI: 10.2174/1874285801307010053     Document Type: Review

References (75)

1. Ayyanar M, Ignacimuthu S. Ethnobotanical survey of medicinalplants commonly used by Kani tribals in Tirunelveli hills of Western Ghats, India. J Ethnopharmacol 2011;134(3): 851-64.
2. Harris ESJ, Erickson SD, Tolopko AN, et al. Traditional MedicineCollection Tracking System (TM-CTS): A database for ethnobota- nically driven drug-discovery programs. J Ethnopharmacol 2011; 135(2): 590-3.
3. Graziose R, Lila MA, Raskin I. Merging traditional chinesemedicine with modern drug discovery technologies to find novel drugs and functional foods. Curr Drug Discov Technol 2010; 7(1): 2-12.
4. Eisenberg DM, Harris ESJ, Littlefield BA, et al. Developing alibrary of authenticated Traditional Chinese Medicinal (TCM) plants for systematic biological evaluation zRationale, methods and preliminary results from a Sino-American collaboration. Fitoterapia 2011; 82(1): 17-33.
5. Anonymous, Antimicrobial resistance. World Health Organization(WHO) Fact sheet NO 194. Reviewed March 2012. Available online at http://www.who.int/mediacentre/factsheets/fs194/en/. Accessed on 2012 December 3.
6. Global Antibiotic Resistance Partnership (GARP) - India Working Group. Rationalizing antibiotic use to limit antibiotic resistance in India. Indian J Med Res 2011; 134(3): 281-94.
7. Oboho KO. Problems of Venereal Disease in Nigeria. 1.Gonococcal resistance to antibiotics and treatment of Gonorrhoea. Fam Pract 1984; 1(4): 219-21.
8. Rice LB. Mechanisms of resistance and clinical relevance ofresistance to beta-lactams, glycopeptides, and Fluoroquinolones. Mayo Clinic Proc 2012; 87(2): 198-208.
9. Hidron AI, Jonathan RE, Patel J, et al. NHSN Annual Update:Antimicrobial-resistant pathogens associated with healthcare- associated infections: Annual summary of data reported to the national healthcare safety network at the centers for disease control and prevention, 2006-2007. Infect Control Hosp Epidemiol 2008; 29(11): 996-1011.
10. Hajjar E, Bessonov A, Molitor A, et al. Toward screening forantibiotics with enhanced permeation properties through bacterial porins. Biochemistry 2010; 49(32): 6928-35.
11. Bolla JM, Alibert-Franco S, Handzlik J, et al. Strategies forbypassing the membrane barrier in multidrug resistant Gram- negative bacteria. FEBS Lett 2011; 585(11): 1682-90.
12. Pagés JM, James CE, Winterhalter M. The porin and thepermeating antibiotic: A selective diffusion barrier in Gram- negative bacteria. Nat Rev Microbiol 2008; 6(12): 893-903.
13. Li XZ, Nikaido H. Efflux-mediated drug resistance in bacteria: Anupdate. Drugs 2009; 69(12): 1555-623.
14. Amaral L, Fanning S, Pagés JM. Efflux pumps of gram-negativebacteria: genetic responses to stress and the modulation of their activity by pH, inhibitors, and phenothiazines. Adv Enzymol Related Areas Mol Biol 2011; 77: 61-108.
15. Nikaido H, Pagés JM. Broad-specificity efflux pumps and their rolein multidrug resistance of Gram-negative bacteria. FEMS Microbiol Rev 2012; 36(2): 340-63.
16. Gunn JS. The Salmonella PmrAB regulon: lipopolysaccharidemodifications, antimicrobial peptide resistance and more. Trends Microbiol 2008; 16(6): 284-90.
17. Delcour AH. Outer membrane permeability and antibioticresistance. Biochim Biophys Acta 2009; 1794(5): 808-16.
18. Chopra I, O'Neill AJ, Miller K. The role of mutators in theemergence of antibiotic-resistant bacteria. Drug Resist Updat 2003; 6(3): 137-45.
19. Romero D, Traxler MF, Lopez D, Kolter R. Antibiotics as signalmolecules. Chem Rev 2011; 111(9): 5492-505.
20. Davies J, Yim G, Davies D. Look who's talking! Microbiol Today 2009; 36(1): 24-27.
21. Yim G, Wang HH, Davies J. Antibiotics as signalling molecules. Philos Trans R Soc Lond B Biol Sci 2007; 362(1483): 1195-200.
22. Rogers GB, Carroll MP, Bruce KD. Enhancing the utility ofexisting antibiotics by targeting bacterial behaviour? Br J Pharmacol 2012; 165(4): 845-57.
23. Trivedi K, Tang CM, Exley RM. Mechanisms of meningococcalcolonisation. Trends Microbiol 2011; 19(9): 456-63.
24. Fischbach MA. Antibiotics from microbes: converging to kill. CurrOpin Microbiol 2009; 12(5): 520-7.
25. Martinez JL, Fajardo A, Garmendia L, et al. A global view ofantibiotic resistance. FEMS Microbiol Rev 2009; 33(1): 44-65.
26. Fischbach MA, Walsh CT, Clardy J. The evolution of genecollectives: How natural selection drives chemical innovation. Proc Natl Acad Sci USA 2008; 105(12): 4601-8.
27. Yim G, McClure J, Surette MG, Davies JE. Modulation ofSalmonella gene expression by subinhibitory concentrations of quinolones. J Antibiot 2011; 64(1): 73-8.
28. Babic F, Venturi V, Maravic-Vlahovicek G. Tobramycin atsubinhibitory concentration inhibits the RhlI/R quorum sensingsystem in a Pseudomonas aeruginosa environmental isolate. BMC Infect Dis 2009; 10: 148.
29. Crawford JM, Clardy J. Bacterial symbionts and natural products. Chem Commun (Camb) 2011; 47(27): 7559-66.
30. Currie CR. A community of ants, fungi, and bacteria: Amultilateral approach to studying symbiosis. Annu Rev Microbiol 2001; 55: 357-80.
31. Clardy J, Fischbach MA, Currie CR. The natural history ofantibiotics. Curr Biol 2009; 19(11): R437-41.
32. Linares JF, Gustafsson I, Baquero F, Martinez JL. Antibiotics asintermicrobiol signaling agents instead of weapons. Proc Natl Acad Sci USA 2006; 103(51): 19484-9.
33. Ryan RP, Dow JM. Diffusible signals and interspeciescommunication in bacteria. Microbiology 2008; 154(7): 1845-58.
34. Hosaka T, Ohnishi-Kameyama M, Muramatsu H, et al. Antibacterial discovery in actinomycetes strains with mutations in RNA polymerase or ribosomal protein S12. Nat Biotech 2009; 27(5): 462-4.
35. Lavigne J-P, Brunel J-M, Chevalier J, Pagés J-M. Squalamine, anoriginal chemosensitizer to combat antibiotic-resistant Gram- negative bacteria. J Antimicrob Chemother 2010; 65(4): 799-801.
36. Salmi C, Loncle C, Vidal N, et al. Squalamine: An appropriatestrategy against the emergence of multidrug resistant gram- negative bacteria? PLoS ONE 2008; 3(7); e2765.
37. Malinverni JC, Silhavy TJ. An ABC transport system thatmaintains lipid asymmetry in the Gram-negative outer membrane. Proc Natl Acad Sci USA 2009; 106(19): 8009-14.
38. Nikaido H. Restoring permeability barrier function to outermembrane. Chem Biol 2005; 12(5): 507-9.
39. Nikaido H. Molecular basis of bacterial outer membranepermeability revisited. microbiol Mol Biol Rev 2003; 67(4): 593-656.
40. Soto SM. Relationship between virulence and antimicrobialresistance in bacteria. Rev Med Microbiol 2009; 20(4): 84-90
41. Cowan SW, Schirmer T, Rummel G, et al. Crystal structuresexplain functional properties of two E. coli porins. Nature 1992; 358(6389): 727-33.
42. Ceccarelli M, Ruggerone P. Physical insights into permeation ofand resistance to antibiotics in bacteria. Curr Drug Targets 2008; 9(9): 779-88.
43. Rodrigues L, Ramos J, Couto I, Amaral L, Viveiros M. Ethidiumbromide transport across Mycobacterium smegmatis cell-wall: Correlation with antibiotic resistance. BMC Microbiol 2011; 11:35.
44. Stephan J, Mailaender C, Etienne G, Daffé M, Niederweis M. Multidrug resistance of a porin deletion mutant of Mycobacterium smegmatis. Antimicrob Agents Chemother 2004; 48(11): 4163-70.
45. Weingart H, Petrescu M, Winterhalter M. Biophysical characteri-zation of in- and efflux in gram-negative bacteria. Curr Drug Targets 2008; 9(9): 789-96.
46. Viveiros M, Dupont M, Rodrigues L, et al. Antibiotic stress,genetic response and altered permeability of E. coli. PLoS ONE 2007; 2(4): e365.
47. Davin-Regli A, Bolla JM, James CE, et al. Membrane permeabilityand regulation of drug influx and efflux in enterobacterial pathogens. Curr Drug Targets 2008; 9(9): 750-9.
48. Dupont M, James CE, Chevalier J, Pagés JM. An early response toenvironmental stress involves regulation of OmpX and OmpF, two enterobacterial outer membrane pore-forming proteins. Antimicrob Agents Chemother 2007; 51(9): 3190-8.
49. Chen S, Zhang A, Blyn LB, Storz G. MicC, a Second Small-RNARegulator of Omp Protein Expression in Escherichia coli. J Bacteriol 2004; 186(20): 6689-97.
50. Chubiz LM, Rao CV. Role of the mar-sox-rob Regulon inRegulating Outer Membrane Porin Expression. J Bacteriol 2011; 193(9): 2252-60.
51. Poole K. Bacterial multidrug efflux pumps serve other functions. Microbe 2008; 3(4): 179-85.
52. Nishino K, Yamaguchi A. Role of xenobiotic transporters inbacterial drug resistance and virulence. IUBMB Life 2008; 60(9): 569-74.
53. Nishino K. Physiological role of bacterial multidrug efflux pumps. Yakugaku Zasshi 2012; 132(1): 45-50.
54. Abdelraouf K, Kabbara S, Ledesma KR, Poole K, Tam VH. Effectof multidrug resistance-conferring mutations on the fitness and virulence of Pseudomonas aeruginosa. J Antimicrob Chemother 2011; 66(6): 1311-7.
55. Piddock LJV. Multidrug-resistance efflux pumps - Not just forresistance. Nature Rev Microbiol 2006; 4(8): 629-36.
56. Nishino K, Nikaido E, Yamaguchi A. Regulation and physiologicalfunction of multidrug efflux pumps in Escherichia coli and Salmonella. Biochim BiophysActa - Proteins Proteomics 2009; 1794(5): 834-43.
57. Varga ZG, Armada A, Cerca P, et al. Inhibition of Quorum Sensingand Efflux Pump System by Trifluoromethyl Ketone Proton Pump Inhibitors. In Vivo. 2012; 26(2): 277-85.
58. Poole K. Efflux pumps as antimicrobial resistance mechanisms. Ann Med 2007; 39(3): 162-76.
59. Vila J, Fabrega A, Roca I, Hernandez A, Martinez JL. Effluxpumps as an important mechanism for quinolone resistance. Adv Enzymol Related Areas Mol Biol 2011; 77: 167-235.
60. Nikaido H. Structure and mechanism of RND-type multidrugefflux pumps. Adv Enzymol Related Areas Mol Biol 2011; 77: 1-60.
61. Nikaido H, Zgurskaya HI. Antibiotic efflux mechanisms. CurrOpin Infec Dis 1999; 12(6): 529-36.
62. Kumar A, Schweizer HP. Bacterial resistance to antibiotics: Activeefflux and reduced uptake. Adv Drug Deliv Rev 2005; 57(10): 1486-513.
63. Vila J, Martinez JL. Clinical impact of the over-expression ofefflux pump in nonfermentative Gram-negative bacilli, development of efflux pump inhibitors. Curr Drug Targets 2008; 9(9): 797-807.
64. Viveiros M, Jesus A, Brito M, et al. Inducement and reversal oftetracycline resistance in Escherichia coli K-12 and expression of proton gradient-dependent multidrug efflux pump genes. Antimicrob Agents Chemother 2005; 49(8): 3578-82.
65. O'Regan E, Quinn T, Pages JM, McCusker M, Piddock L, Fanning S. Multiple regulatory pathways associated with high-level ciprofloxacin and multidrug resistance in Salmonella enterica serovar enteritidis: Involvement of ramA and other global regulators. Antimicrob Agents Chemother 2009; 53(3): 1080-7.
66. Viveiros M, Portugal I, Bettencourt R, et al. Isoniazid-inducedtransient high-level resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2002; 46(9): 2804-10.
67. Martins A, Iversen C, Rodrigues L, et al. An AcrAB-mediatedmultidrug-resistant phenotype is maintained following restoration of wild-type activities by efflux pump genes and their regulators. Int J Antimicrob Agents 2009; 34(6): 602-4.
68. Mulkidjanian AY, Heberle J, Cherepanov DA. Protons @interfaces: Implications for biological energy conversion. Biochim Biophys Acta - Bioenergetics 2006; 1757(8): 913-30.
69. Chevalier J, Mahamoud A, Baitiche M, et al. Quinazolinederivatives are efficient chemosensitizers of antibiotic activity in Enterobacter aerogenes, Klebsiella pneumoniae and Pseudomonas aeruginosa resistant strains. Int J Antimicrob Agents 2010; 36(2): 164-8.
70. Singh M, Jadaun GP, Ramdas, et al. Effect of efflux pumpinhibitors on drug susceptibility of ofloxacin resistant Mycobacterium tuberculosis isolates. Indian J Med Res 2011; 133: 6.
71. Abbate E, Vescovo M, Natiello M, et al. Successful alternativetreatment of extensively drug-resistant tuberculosis in Argentina with a combination of linezolid, moxifloxacin and thioridazine. J Antimicrob Chemother 2011; 67(2): 473-7.
72. Sharma S, Singh A. Phenothiazines as anti-tubercular agents:mechanistic insights and clinical implications. Expert Opin Investig Drugs 2011; 20(12): 1665-76.
73. Amaral L, Molnar J. Potential therapy of multidrug-resistant andextremely drug-resistant tuberculosis with thioridazine. In Vivo 2012; 26(2): 231-6.
74. Martins M. Targeting the human macrophage with combinations ofdrugs and inhibitors of Ca2+ and K+ transport to enhance the killing of intracellular multi-drug resistant mycobacterium tuberculosis (MDR-TB) - a novel, patentable approach to limit the emergence of XDR-TB. Recent Pat Antiinfect Drug Discov 2011; 6(2): 110-7.
75. Amaral L, Martins A, Molnar J, et al. Phenothiazines, bacterialefflux pumps and targeting the macrophage for enhanced killing of intracellular XDRTB. In Vivo 2010; 24(4): 409-24.